{"id":115328,"date":"2026-07-27T11:16:15","date_gmt":"2026-07-27T05:46:15","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=115328"},"modified":"2026-07-27T11:16:15","modified_gmt":"2026-07-27T05:46:15","slug":"generic-drug-tariff-threat","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/generic-drug-tariff-threat\/","title":{"rendered":"Generic Drug Tariff Threat: Implications for Indian Pharma and Global Supply Chains"},"content":{"rendered":"<h2><b>Generic Drug Tariff Threat Latest News<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">US President Donald Trump announced recently, that tariffs on generic drugs will be raised to 100% after two years and to 200% thereafter, aimed at &#8220;reshoring&#8221; generic pharmaceutical production to the US.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">He warned that companies choosing not to build plants in the US would be &#8220;penalised.&#8221;<\/span><\/li>\n<\/ul>\n<h2><b>Context: A Pattern of Tariff Threats<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">This is not Trump&#8217;s first such threat on medicines:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">April 2, 2026: Announced tariffs of up to 100% on specified branded medicines, set to start July 31, under the Section 232 national security framework.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">September 25, 2025: Announced plans for a 100% tariff on imported branded and patented medicines.<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Neither earlier proposal has been implemented.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Notably, actual tariffs on drugs have been exempted in most tariff instruments used by the Trump administration so far \u2014 including those under the International Emergency Economic Powers Act, Section 122 of the 1974 Trade Act, and Section 232 of the Trade Expansion Act of 1962.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Experts believe these threats are primarily designed to <\/span><b>pressure global pharma giants into boosting US investments<\/b><span style=\"font-weight: 400;\">, rather than to actually raise tariffs \u2014 which could trigger domestic backlash, especially close to US midterm elections.<\/span><\/li>\n<\/ul>\n<h2><b>Why This Matters for India<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The US is India&#8217;s <\/span><b>largest pharmaceutical export market<\/b><span style=\"font-weight: 400;\">, accounting for almost 40% of India&#8217;s pharma exports.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Around 90% of India&#8217;s pharmaceutical exports to the US are generic medicines.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In 2025, India exported $9.7 billion worth of pharmaceuticals to the US.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The US imported $213 billion worth of pharmaceutical products in 2025 overall, including $94.1 billion in finished medicines sold in retail packs \u2014 the category covering generics.<\/span><\/li>\n<\/ul>\n<h2><b>Indian Pharma&#8217;s Response: Rising US Investment<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tariff-related uncertainty appears to be driving Indian pharma companies to secure US market access through investment:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Sun Pharmaceutical Industries (India&#8217;s largest pharma company) announced the acquisition of US-listed Organon &amp; Co. for $11.8 billion \u2014 the largest overseas acquisition by an Indian pharmaceutical company to date.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">As per a report, April 2026 recorded 103 M&amp;A transactions worth $18.7 billion \u2014 the highest monthly deal value since May 2022, driven significantly by the Sun Pharma-Organon deal.<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Outbound investment trend<\/b><span style=\"font-weight: 400;\"> (Commerce Ministry data, Lok Sabha reply):<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">FY26: <\/span><b>$4.08 billion<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">FY25: $3.44 billion<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">FY24: $2.44 billion<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">This year&#8217;s outbound pharma investment already exceeds the combined total of the previous four years.<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Beyond pharma<\/b><span style=\"font-weight: 400;\">: India&#8217;s steel sector is also increasing US investment \u2014 JSW Steel announced $500 million in plans for Ohio and Texas.<\/span><\/li>\n<\/ul>\n<h2><b>Existing US Manufacturing Presence<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">According to the Global Trade Research Initiative (GTRI), several major Indian drugmakers already operate US-based, FDA-approved manufacturing facilities:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla, and Dr Reddy&#8217;s Laboratories;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Cipla is expanding production at plants in Massachusetts and New York;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Dr Reddy&#8217;s has signalled willingness to increase US manufacturing if commercially viable.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2><b>Why Full Relocation Is Unlikely<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">GTRI cautions that large-scale relocation of generic drug production to the US faces structural hurdles:<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Generic medicines operate on <\/span><b>extremely thin margins<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Production depends on global supply chains, especially for <\/span><a href=\"https:\/\/vajiramandravi.com\/current-affairs\/what-are-active-pharmaceutical-ingredients-apis\/\" target=\"_blank\"><b>Active Pharmaceutical Ingredients (APIs)<\/b><\/a><span style=\"font-weight: 400;\">, many sourced from India and China.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Building a fully domestic US supply chain would require substantial investment and would <\/span><b>almost certainly raise medicine prices<\/b><span style=\"font-weight: 400;\"> in the US.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2><b>Conclusion<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">While Trump&#8217;s 200% tariff threat has not yet materialised into policy, it is already reshaping Indian pharma&#8217;s strategic calculus \u2014 accelerating outbound investment and US-based manufacturing expansion as a hedge against future trade uncertainty.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">However, the deep cost and supply-chain advantages of Indian generic manufacturing make a full reshoring of production to the US economically implausible in the near term.<\/span><\/li>\n<\/ul>\n<p><b>Source:<\/b> <strong><a href=\"https:\/\/indianexpress.com\/article\/explained\/explained-economics\/trump-generic-drug-tariffs-indian-pharma-us-impact-10798676\/\" target=\"_blank\" rel=\"nofollow noopener\">IE<\/a> | <a href=\"https:\/\/www.thehindu.com\/business\/make-in-us-by-august-2028-or-pay-up-to-200-duty-trump-tells-generic-drugmakers\/article71254793.ece\" target=\"_blank\" rel=\"nofollow noopener\">TH<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Generic Drug Tariff Threat could affect Indian pharmaceutical exports, US healthcare costs, investment decisions and global pharmaceutical supply chains.<\/p>\n","protected":false},"author":18,"featured_media":115344,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18],"tags":[8984,60,22,59],"class_list":["post-115328","post","type-post","status-publish","format-standard","has-post-thumbnail","category-upsc-mains-current-affairs","tag-generic-drug-tariff-threat","tag-mains-articles","tag-upsc-current-affairs","tag-upsc-mains-current-affairs-tag","no-featured-image-padding"],"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/115328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=115328"}],"version-history":[{"count":3,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/115328\/revisions"}],"predecessor-version":[{"id":115367,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/115328\/revisions\/115367"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/115344"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=115328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=115328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=115328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}